Patents by Inventor David Anthony Barda

David Anthony Barda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS INHIBITORS
    Publication number: 20250289830
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: May 29, 2025
    Publication date: September 18, 2025
    Inventors: David Anthony BARDA, Mario BARBERIS, Jolie Anne BASTIAN, Matthew Patrick BAUMGARTNER, Santiago CARBALLARES MARTIN, Kelly Wayne FURNESS, Pablo GARCIA LOSADA, Deqi GUO, Sonia Maria GUTIERREZ SANFELICIANO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLÓREZ, Maria Lourdes PRIETO VALLEJO, Michael John RODRIGUEZ, Isabel ROJO, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI
  • KRas inhibitors
    Patent number: 12351591
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Grant
    Filed: March 24, 2023
    Date of Patent: July 8, 2025
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Anthony Barda, Jolie Anne Bastian, Kelly Wayne Furness, Deqi Guo, James Robert Henry, Richard Duane Johnston, Jason Eric Lamar, Tao Liu, Michael John Rodriguez, Almudena Rubio, Chong Si, Gaiying Zhao, Mohammad Sadegh Zia-Ebrahimi, Matthew Patrick Baumgartner, Isabel Rojo, Mario Barberis, Santiago Carballares Martin, Pablo Garcia Losada, Sonia Maria Gutierrez Sanfeliciano, Wenceslao Lumeras Amador, Victoriano Molero Florez, Maria Lourdes Prieto Vallejo
  • SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS
    Publication number: 20240228511
    Abstract: The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: June 8, 2022
    Publication date: July 11, 2024
    Inventors: David Anthony BARDA, Joshua Ryan CLAYTON, Jeffry Bernard FRANCISKOVICH, Kelly Wayne FURNESS, Douglas Linn GERNERT, James Robert HENRY, Richard Duane JOHNSTON, Spencer Brian JONES, Jason Eric LAMAR, Adam Marc LEVINSON, Curren Tapfuma MBOFANA, Michael John RODRIQUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammed Sadegh ZIA-EBRAHIMI
  • KRAS INHIBITORS
    Publication number: 20240043451
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: March 24, 2023
    Publication date: February 8, 2024
    Inventors: David Anthony BARDA, Jolie Anne BASTIAN, Kelly Wayne FURNESS, Deqi GUO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Michael John RODRIGUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI, Matthew Patrick BAUMGARTNER, Isabel ROJO, Mario BARBERIS, Santiago CARBALLARES MARTIN, Pablo GARCIA LOSADA, Sonia Maria GUTIERREZ SANFELICIANO, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLOREZ, Maria Lourdes PRIETO VALLEJO
  • KRas G12C inhibitors
    Patent number: 10968214
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: April 6, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, David Andrew Coates, Ryan James Linder, Sheng-Bin Peng, Mohammad Sadegh Zia-Ebrahimi
  • KRAS G12C INHIBITORS
    Publication number: 20200115375
    Abstract: The present invention provides compounds of the Formula I below where R1, R2 and m are as described herein, pharmaceutically acceptable salts of the compounds of Formula 1, and methods of using these compounds and salts for treating patients for cancer.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 16, 2020
    Inventors: David Anthony BARDA, David Andrew COATES, Ryan James LINDER, Sheng-Bin PENG, Mohammad Sadegh ZIA-EBRAHIMI
  • PI3 kinase/mTOR dual inhibitor
    Patent number: 8658668
    Abstract: The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: February 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Mary Margaret Mader
  • PI3 KINASE/mTOR DUAL INHIBITOR
    Publication number: 20130237562
    Abstract: The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: September 12, 2013
    Applicant: Eli Lilly and Company
    Inventors: David Anthony Barda, Mary Margaret Mader
  • PI3 kinase/mTOR dual inhibitor
    Patent number: 8440829
    Abstract: The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: May 14, 2013
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Mary Margaret Mader
  • PI3 KINASE/mTOR DUAL INHIBITOR
    Publication number: 20120184577
    Abstract: The present invention provides an imidazo[4,5-c]quinolin-2-one compound, or a pharmaceutically acceptable salt thereof, that inhibits both PI3K and mTOR and, therefore, is useful in the treatment of cancer.
    Type: Application
    Filed: January 11, 2012
    Publication date: July 19, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: David Anthony Barda, Mary Margaret Mader
  • Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors
    Patent number: 7666879
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: February 23, 2010
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander McLean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Mai Yip, Boyu Zhong
  • IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS
    Publication number: 20090227622
    Abstract: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
    Type: Application
    Filed: February 23, 2006
    Publication date: September 10, 2009
    Inventors: David Anthony Barda, Timothy Paul Burkholder, Joshua Ryan Clayton, Yan Hao, James Robert Henry, John Monte Knobeloch, Johnathan Alexander Mclean, David Mendel, Mark Edward Rempala, Zhao-Qing Wang, Yvonne Yee Yip, Boyu Zhong
  • 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
    Patent number: 7449477
    Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: November 11, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Kenneth James Henry, Jr., Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Enrico Richett
  • Inhibitors of Akt (protein kinase B)
    Patent number: 7414063
    Abstract: The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rima Salim Al-Awar, David Anthony Barda, Albert Gerard Dee, Kenneth James Henry, Jr., Sajan Joseph, Ho-Shen Lin, Jose Eduardo Lopez, Michael Enrico Richett, Carmen Somoza
  • Potentiators of glutamate receptors
    Publication number: 20040006114
    Abstract: The present invention relates to potentiators of metabotropic glutamate receptor function and specifically provides compounds of formula I, compositions thereof and methods of using the same.
    Type: Application
    Filed: November 20, 2002
    Publication date: January 8, 2004
    Inventors: Darrell Stephen Coleman, Gunnar Erik Jagdmann, Kirk Willis Johnson, Michael Parvin Johnson, Thomas Hallett Large, James Allen Monn, Darryle Darwin Schoepp, David Anthony Barda, Thomas Charles Britton, Bruce Anthony Dressman, Steven Scott Henry, William Joseph Hornback, Joseph Patrick Tizzano, Michael William Fichtner